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To the Editor: Canaud et al.1 reported a significant 35%
lower mortality risk with high-efficiency hemodiafiltration
(HDF) compared to low-flux hemodialysis. Patients on HDF
were slightly older, significantly heavier, and longer on renal
replacement therapy (higher co-morbidity). Thus, they were
possibly selected for HDF because of their higher risk profile.
We evaluated HDF data prospectively collected in EuCliD2
from 56 clinics in Czech Republic, Hungary, Italy, and UK, all
belonging to an International dialysis provider network. To
reduce bias related to different dialysis doses, only patients on
three times a week schedule achieving an eKt/VX1.20 were
considered. Out of 2564 prevalent patients, 394 were treated
with HDF and 2170 with hemodialysis over 12 months.
Similarly, patients on HDF were heavier (67.6 versus 65.9 kg,
P¼ 0.03) and longer on renal replacement therapy (6.6174.94
versus 4.9775.05 years, Po0.001); however, they were
significantly younger (52.7716.3 versus 59.7716.1 years,
Po0.001). Furthermore, they were more likely to be diabetic
(20.3 versus 18.3%) or affected by neoplasm (8.4 versus 6.7%).
High-flux polysulfone was usually used. Data on replacement
volume is not currently available but, as on-line HDF was
standard, volumes are likely to be high (15–25 l).
HDF resulted in a significant 42.7% reduction in mortality
risk (odds ratio: 0.573; 95% confidence interval: 0.377–0.873).
After adjustment for age, gender, co-morbidities, and time on
renal replacement therapy, mortality risk reduction was 35.3%
(odds ratio: 0.647; 95% confidence interval: 0.419–0.991) and
remained significant. In conclusion, our data confirm the
results of Canaud et al.1 However, epidemiological evaluations
have limitations. The potential survival benefit of HDF must
be tested by controlled clinical trials.
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Jirka et al.1 submit a very interesting letter confirming the
results recently reported with the International Dialysis
Outcomes and Practice Patterns Study.2 They observed a
35.3% reduction rate in mortality risk in online hemodia-
filtration (HDF)-treated patients belonging to an interna-
tional dialysis care provider (Fresenius Medical Care, Bad
Homburg, Germany), after adjustment for age, co-morbid-
ities, and time on dialysis. These data were prospectively
collected over 12 months through the European Clinical
Database (Euclid) network in 56 clinics. This database
includes 2564 prevalent hemodialysis patients, out of them
394 were treated by online HDF. Online HDF was
comparable in terms of efficacy to the high-efficiency
group of Dialysis Outcomes and Practice Patterns Study
with a 15–25 l fluid exchanged per session and a Kt/V
superior to 1.2. Today, it is not still well understood why
these convective therapies are superior to hemodialysis.
However, one can speculate that by enhancing both the
removal of middle molecules toxins (e.g., B2M) and the
biocompatibility of the dialysis system (ultrapurity of
dialysate, highly permeable synthetic membranes), these
methods improve substantially the efficiency and the
quality of the delivered treatment.3 As suggested by Jirka
et al.1 prospective controlled randomized studies hemo-
dialysis versus HDF are missing. This lack will be certainly
corrected with the three European ongoing studies on this
topic.4 This brief report is, nevertheless, a very strong
support to our findings showing that high-efficiency conve-
ctive therapies, such as online HDF, may offer an interesting
alternative to improve dialysis patient outcomes.
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Cholesterol crystal embolism:
Diagnostic and treatment
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To the Editor: In his recent in-depth review of cholesterol
crystal embolization syndrome (CCE), Meyrier1 has deli-
neated the pathogenesis, differential diagnoses, and thera-
peutic aspects of CCE. In addition to therapeutic measures of
paramount importance such as restriction of further
intravascular interventions, stop of anticoagulation, and
treatment of renal insufficiency with dialysis, we would
like to add the possibility of performing renal transplantation
in selected CCE cases with end-stage renal disease and
stable clinical course after diagnosis of CCE. We have
previously reported a patient with CCE successfully under-
going renal transplantation.2 According to the best of our
knowledge, there are so far no other published cases of the
renal transplantation after CCE-induced end-stage renal
disease.
Briefly, a 63-year-old patient with a high load of
atherosclerotic risk factors (heavy smoker, hypertension
160/80–180/100 mm Hg, severe hyperlipidemia (triglycerides
up to 500 mg/dl; low-density lipoprotein cholesterol up to
240 mg/dl)) suffered from end-stage renal disease owing to
cholesterol emboli after coronary angiography because of
symptomatic coronary artery disease in October 1997.
Within 1 week, the patient developed renal failure necessitat-
ing hemodialysis since December 1997. Smoking cessation,
effective control of blood pressure (o130/80 mm Hg), and
serum lipids (low-density lipoprotein cholesterol o100 mg/
dl) was achieved and maintained until successful renal
transplantation from a living related donor in 1998. Until
his last follow-up in May 2006, kidney function has remained
stable with a current serum creatinine level of 1.28 mg/dl,
corresponding to a calculated creatinine clearance of 60 ml/
min. Serum lipids have remained normalized with diet and
pravastatin therapy (40 mg/day) with total cholesterol levels
of about 187 mg/dl and low-density lipoprotein cholesterol
levels of about 120 mg/dl as well as normotensive blood
pressure levels have been achieved with losartan, doxazosin,
nitrendipin, and nebivolol combined antihypertensive ther-
apy, and the patient refrained from smoking.
In conclusion, secondary prevention of CCE, that is, rigid
long-term control of the underlying atherosclerotic risk
factors may enable a selected subgroup of patients with CCE
to undergo successful renal transplantation with excellent
long-term patient and graft survival.
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Kryvoshey et al.’s experience1 with renal transplantation to
treat end-stage renal disease following cholesterol crystal
embolism to the kidney is quite interesting. That renal
replacement was not complicated by relapse of cholesterol
crystal embolism on the transplant confirms the interest of
stabilizing atherosclerotic plaques with statins, as already
shown by Scolari et al.2 However, patients with massive
cholesterol crystal embolism do not die from renal failure
but from vital organ injury, such as mesenteric and
pancreatic ischemia. From this standpoint, the writers of
this letter confirm the essential role of preventing
cholesterol crystal embolism in patients at risk, that is,
lifelong smokers with lipid disorders and widespread
atherosclerosis.
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Cardiac troponins and chronic
kidney disease
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To the Editor: We were interested in the recent paper by
Kanderian and Francis1 in which they review hypothetical
mechanisms contributing to the increase in serum troponin
concentrations observed in chronic kidney disease (CKD).
The work of Diris et al.,2 who demonstrated fragments of the
cardiac troponin T (cTnT) molecule ranging in size from 8 to
25 kDa in hemodialysis patients, is discussed. It is suggested
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